A 26-year-old woman presents with a 3-day history of dysuria, urinary frequency, and purulent urethral discharge. On urethroscopy, urethritis is confirmed. Gram stain of the urethral exudate shows Gram-negative intracellular diplococci within polymorphonuclear leukocytes. Nucleic acid amplification testing (NAAT) for *Chlamydia trachomatis* is negative. What is the most appropriate treatment regimen?

Explanation

## Clinical Diagnosis **Key Point:** The clinical presentation (dysuria, purulent urethral discharge) combined with Gram stain findings (Gram-negative intracellular diplococci in PMNs) and negative *Chlamydia* NAAT is diagnostic of **gonorrhea** caused by *Neisseria gonorrhoeae*. ## Gram Stain Interpretation | Feature | Finding | Significance | |---------|---------|-------------| | Morphology | Gram-negative diplococci | Characteristic of *N. gonorrhoeae* | | Location | Intracellular (within PMNs) | Pathognomonic for gonorrhea | | Gram stain sensitivity | ~90% in urethritis | Highly specific when positive | | *Chlamydia* NAAT | Negative | Rules out non-gonococcal urethritis (NGU) | ## Current Treatment Guidelines **High-Yield:** Antibiotic resistance in *N. gonorrhoeae* has evolved dramatically: - **Penicillin:** Widespread resistance (>50% in many regions); no longer recommended. - **Tetracyclines:** Widespread resistance; no longer recommended. - **Fluoroquinolones:** Resistance increasing; no longer recommended by WHO/CDC. - **Cephalosporins:** Remain effective; 3rd-generation cephalosporins are first-line. **Clinical Pearl:** Current CDC/WHO guidelines recommend **ceftriaxone + azithromycin** as the gold standard for uncomplicated gonorrhea. This combination provides: 1. High cure rates (>99%) for uncomplicated urethritis. 2. Coverage of potential co-infection with *Chlamydia* (even if NAAT negative, co-infection occurs in 20–40% of cases). 3. Synergistic activity against resistant strains. **Mnemonic:** **CAG** — **C**eftriaxone + **A**zithromycin = **G**onorrhea. ## Why Option 0 Is Correct - **Ceftriaxone 500 mg IM single dose:** Excellent coverage of *N. gonorrhoeae*, including penicillin- and fluoroquinolone-resistant strains. Achieves high urethral concentrations. - **Azithromycin 1 g PO single dose:** Covers potential *Chlamydia* co-infection and provides additional anti-gonococcal activity. Recommended even when *Chlamydia* NAAT is negative because co-infection is common and NAAT may have false-negative results. - This is the **WHO and CDC recommended regimen** for uncomplicated gonorrhea [cite:CDC STI Treatment Guidelines 2021]. ## Why Other Options Are Suboptimal - **Penicillin G monotherapy:** Widespread penicillin resistance in *N. gonorrhoeae* (>50% resistance in many countries); treatment failure rate is unacceptably high. - **Tetracycline:** Widespread resistance in *N. gonorrhoeae*; no longer recommended. Also does not cover potential *Chlamydia* co-infection adequately. - **Fluoroquinolone monotherapy:** Increasing resistance; no longer recommended by WHO or CDC. Treatment failure rates are rising globally. **Warning:** Do not use penicillin, tetracyclines, or fluoroquinolones as monotherapy for gonorrhea. Resistance is widespread and treatment failure is common.